Premier Alternatives

Repair Biotechnologies

Syracuse, NY · Founded 2018 · Privately Held (backing)

Operator of a preclinical biotechnology company intended to develop drugs for cholesterol and aging-related diseases. Repair Biotechnologies is based in Syracuse, NY and was founded in 2018. It was valued at $74.4 million at its seed round in Nov 2025, the last priced event on record. It has raised $22.9 million across 6 recorded rounds; the latest was a $5.3 million early-stage round in Nov 2025.

PMV mark · valuation
$74.4M
Oct 2026
Priced at
its seed round
Nov 2025
Total raised
$22.9M
Last round
Early Stage VC
Nov 2025

Repair Biotechnologies key facts

as of Oct 2026
  • Operator of a preclinical biotechnology company intended to develop drugs for cholesterol and aging-related diseases.
  • Repair Biotechnologies is valued at approximately $74.4M as of Oct 2026, set at its seed round, Nov 2025; nothing has traded since, per PrivateMarketView’s mark.
  • It has raised $22.9M across 6 recorded rounds; the latest was Early Stage VC ($5.3M) in Nov 2025.
  • Notable investors include 100 Plus Capital, Bioverge Ventures, Emerging Longevity Ventures, Healthspan Capital, James Mellon — 14 tracked in total.
  • Repair Biotechnologies has filed 8 Form Ds with the SEC since 2018, most recently Mar 2024 ($6.2M sold to 7 investors).
  • Status: Privately Held (backing).
PrivateMarketView mark
MEDIUM confidence
$74.4M

Valued at $74.4M at its seed round, Nov 2025. Nothing has traded since.

set by its last priced roundas of Oct 2026question about this number?
Free account
More of Repair Biotechnologies with a free account
  • ·The complete investor list: 14 names
  • ·Watch Repair Biotechnologies: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Repair Biotechnologies funding rounds

6 rounds
Nov 2025Early Stage VC$5.3MSEC filing▮
Mar 2024Early Stage VC$6.2MSEC filing▮
Jun 2023Early Stage VC$8.4MSEC filing▮
Aug 2020Seed Round$2.9MSEC filing▮
Mar 2019Seed Round$2.1MSEC filing▮
Full funding history →

Repair Biotechnologies valuation

Repair Biotechnologies was valued at $74.4 million at its seed round in Nov 2025. That is the last priced event on record: no secondary trade or institutional fund mark has moved the figure since.

How much has Repair Biotechnologies raised?

Repair Biotechnologies has raised $22.9 million across 6 recorded rounds since 2018. The largest was an $8.4 million early-stage round in Jun 2023; the most recent was a $5.3 million early-stage round in Nov 2025.

Repair Biotechnologies has filed 8 Form Ds with the SEC since 2018, most recently in Mar 2024 ($6.2 million sold to 7 investors).

Repair Biotechnologies investors

14 investors are on record for Repair Biotechnologies, including 100 Plus Capital, Bioverge Ventures, Emerging Longevity Ventures and Healthspan Capital. The early-stage round in Nov 2025 drew 16 investors.

About Repair Biotechnologies

Operator of a preclinical biotechnology company intended to develop drugs for cholesterol and aging-related diseases. The company's cholesterol-degrading platform (CDP) technology is aimed at reversing atherosclerosis, familial hypercholesterolemia, and other conditions in which excess or modified cholesterol drives pathology, enabling healthcare providers to rapidly and dramatically reduce atherosclerotic plaque in arteries, the cause of stroke, heart attack, and other cardiovascular diseases.

Sector
Healthcare
HQ
Syracuse, NY, United States
Founded
2018
Employees
10
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.